Comparative study of laparoscopic radical gastrectomy and open radical gastrectomy

Conclusion: Laparoscopic radical gastrectomy is superior to open surgery in the aspects of intra-operative blood loss, post-operative exhaust time, post-operative hospital stay and timing of drain removal. With the number of laparoscopic radical gastrectomy cases increased, the duration of surgery is shortened and the amount of intra-operative blood loss will decrease.
Source: Journal of Minimal Access Surgery - Category: Surgery Authors: Source Type: research

Related Links:

In conclusion, DDX11-AS1 may serve as an oncogene in GC progression by sponging miR-873-5p and promoting SPC18 expression, providing a new insight into the mechanisms of DDX11-AS1 and elucidating a promising therapy target in GC. PMID: 32054332 [PubMed - in process]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
ConclusionsWe developed the SPACiAL workflow to provide immunohistochemistry-guided in situ metabolomics on intact tissue sections. Diminishing the workload by automated recognition of histological and functional features, the pipeline allows comprehensive analyses of metabolic heterogeneity. The multimodality of immunohistochemical staining and extensive molecular information from imaging mass spectrometry has the advantage of increasing both the efficiency and precision for spatially resolved analyses of specific cell types. The SPACiAL method is a stepping stone for the objective analysis of high-throughput, multi-omics...
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has been demonstrated. However, it is unclear whether trastuzumab can show similar efficacy as a second-line treatment for gastric cancer. Here, we report that trastuzumab in combination with paclitaxel exhibits increased antitumor efficacy even for trastuzumab-resistant xenografted tumors. We derived the trastuzu...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
The aim of this study was to evaluate the efficacy and safety of modified docetaxel, oxaliplatin, capecitabine (DOC) combination chemotherapy, followed by maintenance capecitabine as first-line therapy for patients with metastatic gastric or gastroesophageal junction (GEJ) cancer. Treatment consisted of docetaxel 35 mg/m2 (days 1–8), l-OHP 85 mg/m2 (day 1), and capecitabine 750 mg/m2 twice daily (days 1–14), every 3 weeks. After six cycles of DOC, patients who did not progress received maintenance treatment with three-weekly capecitabine 1000 mg/m2 twice daily (days 1–14...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
In this study, we conducted a comprehensive analysis of the systemic levels of selected growth factors - hepatocyte, vascular-endothelial, fibroblast, and insulin-like 1 growth factors (HGF, VEGF, FGF, and IGF-1, respectively), as well as granulocyte-colony stimulating factor (G-CSF) in 75 patients with different gastric neoplasms (carcinomas, gastrointestinal stromal tumors - GISTs, neuroendocrine neoplasms - NENs, and lymphomas) and 40 healthy volunteers. Patients with gastric carcinoma or other types of gastric neoplasms had higher HGF and IGF-1 levels than healthy individuals (P
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Conclusions: The inhibitory effects of ectopic KLF4 could be attenuated by co-transfection of miR-135b-5p. Collective data suggested that miR-135b-5p has a tumor-promoting role in GC cells via downregulating KLF4. Hence, inhibition of miR-135b-5p could be valuable for treatment of gastric cancer. PMID: 32051721 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
Publication date: Available online 13 February 2020Source: Pathology - Research and PracticeAuthor(s): Yanfeng Xi, Chen Xu, Yiqiang Liu, Xiaochu Yan, Chuansheng Huang, Yueping Liu, Jinhong Mei, Zhe Wang, Bin Liu, Xiaoming Li, Wencai Li, Jianyun Lan, Peng Gao, Jifeng Wu, Jianming Zheng, Yingyong HouAbstractAimsThe aim of this study was to explore HER2 status and characteristics in biopsy specimens of gastric cancer (GC) in Chinese population.Methods and resultsA total of 27787 biopsy specimens of GC from 103 hospitals were obtained. Immunohistochemistry (IHC) staining of HER2 was performed. Overall HER2 IHC positive rate wa...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 13 February 2020Source: Pathology - Research and PracticeAuthor(s): Xiaoqiao Liu, Min Gew Choi, Kyung Kim, Kyoung-Mee Kim, Seung Tae Kim, Se Hoon Park, Razvan Cristescu, Senaka Peter, Jeeyun LeeAbstractBackgroundThe programmed death receptor ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay is a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients, especially in the U.S. The present study investigated the relationship between PD-L1 expression and the clinical features, molecular markers, and molecular subtypes of GC.MethodsPD-L1 expression ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
ConclusionRecurrent FGFR2 amplification was observed in roughly 4.0% of GC patients. High FGFR2 amplification was significantly associated with poor progression free survival and overall survival in GC patients. Clinical studies of FGFR2-directed therapies are warranted and should consider stratification by FGFR2 CNA.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusions: AFAP1-AS1 might be an oncogenic lncRNA that promoted GC progression by acting as a competing endogenous RNA (ceRNA) that regulates the expression of FGF7 through sponging miR-155-5p, suggesting that AFAP1-AS1 may be a novel potential therapeutic target for GC. PMID: 32051698 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Laparoscopy | Laparotomy | Statistics | Study | Surgery